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Aim To investigate the time trends of leukemia and lym-
phoma  in  Croatia  from  1988-2009,  compare  them  with 
trends in other populations, and identify possible changes.
Methods The  data  sources  were  the  Croatian  National 
Cancer Registry for incidence data, Croatian Bureau of Sta-
tistics for the numbers of deaths, and United Nations pop-
ulation estimates. Joinpoint regression analysis using the 
age-standardized rates was used to analyze incidence and 
mortality trends.
Results Acute lymphoblastic leukemia and chronic lym-
phocytic leukemia incidence did not significantly change. 
Acute myeloid leukemia incidence significantly increased 
in  women,  with  estimated  annual  percentage  change 
(EAPC) of 2.6% during the whole period, and in men since 
1998, with EAPC of 3.2%. Chronic myeloid leukemia inci-
dence significantly decreased in women (EAPC -3.7%) and 
remained stable in men. Mortality rates were stable for 
both lymphoid and myeloid leukemia in both sexes. Hodg-
kin  lymphoma  non-significantly  increased  in  incidence 
and significantly decreased in mortality (EAPCs of -5.6% in 
men and -3.7% in women). Non-Hodgkin lymphoma sig-
nificantly increased in incidence in women (EAPC 3.2%) 
and non-significantly in men and in mortality in both men 
(EAPC 1.6%) and women (EAPC 1.8%).
Conclusion While Croatia had similar leukemia and lym-
phoma incidence trends as the other countries, the mor-
tality trends were less favorable than in Western Europe. 
The lack of declines of leukemia incidence and non-Hodg-
kin lymphoma mortality could be attributed to late intro-
duction of optimal therapies. As currently the most up-to-
date diagnostics and treatments are available and covered 
by health insurance, we expect more favorable trends in 
the future.
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FIgure 1. Incidence trends of hematopoietic malignancies in Croatia, 1988-2009, rhombs – male; triangles – female; ASr  (W)– age-standardized rate per 
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Leukemias and lymphomas contribute 5% to the overall 
cancer incidence in Croatia (1). They comprise disease en-
tities diverse in etiology, incidence, prognosis, and treat-
ment. The  four  major  leukemia  subtypes  include  acute 
lymphoblastic leukemia (ALL), chronic lymphocytic leuke-
mia (CLL), acute myeloid leukemia (AML), and chronic my-
eloid leukemia (CML), while lymphomas include Hodgkin 
lymphoma (HL) and non-Hodgkin lymphoma (NHL).
Estimated 5-year relative survival for patients diagnosed be-
tween 2000 and 2002 in Europe, according to EUROCARE-4 
results, is 43.4% for the overall group of leukemias. CLL has 
the highest 5-year survival rate (70.2%), followed by CML 
(37.2%), ALL (28.8%), and AML (15.8%). Five-year survival rates 
for lymphomas were 81.9% for HL and 53.6% for NHL (2).
Recognized environmental risk factors for leukemia are ex-
posure to ionising radiation (3-5), chemicals such as benzene 
(6), pesticides (7), chemotherapy (8), cigarette smoking (9), 
genetic disorders (10,11), family history in case of CLL (12), 
infection with HTLV-I (13), socio-economic status (14), and 
obesity (15). However, those risk factors could explain only 
minority of cases, and leukemia etiology remains largely un-
known. Environmental risk factors for NHL are exposure to 
pesticides, solvents (16,17) and HIV infection (18), while those 
for HL include HIV (19) and Epstein-Barr virus infection (20).
The last decades brought significant improvements in di-
agnosis and treatment of leukemias and lymphomas. The 
aim of our study was to investigate the time trends of leu-
kemia and lymphoma in Croatia from 1988-2009, compare 




Incidence data for the period 1988-2009 were obtained 
from the Croatian National Cancer Registry. The Registry, 
founded in 1959, covers the whole Croatian population 
(approximately  4.4  million  persons),  and  relies  on  man-
datory cancer notifications from primary and secondary 
health care sources and death certificates from the Croa-
tian Bureau of Statistics. The Registry contributed data to 
the last three volumes of the Cancer Incidence in Five Con-
tinents series (21-23). Leukemia and lymphoma were de-
fined as ICD-9 codes 201 (HL), 202 (NHL), 204 (lymphoid 
leukemia), 204.0 (ALL), 204.1 (CLL), 205 (myeloid leukemia), 
205.0 (AML), 205.1 (CML) and ICD-10 codes C81 (HL), C82-
85 (NHL), C91 (lymphoid leukemia), C91.0 (ALL), C91.1 (CLL), 
C92 (myeloid leukemia), C92.0 (AML), C92.1 (CML) (24). The 
numbers of cancer deaths were obtained from WHO mor-
tality database, and were not available with 4 ICD digits 
(25). For calculating age-specific rates we used the United 
Nations population estimates (26).
Statistical analysis
Age-standardized rates of cancer incidence in Croatia were 
calculated by the direct standardization method, using the 
world standard population as a reference (27). To describe 
incidence and mortality trends by calendar period, we car-
ried out joinpoint regression analysis using the Joinpoint 
Regression Software (28). The analysis included logarithmic 
transformation of the rates, standard error, maximum num-
ber of five joinpoints, and minimum of four years between 
two joinpoints. All other program parameters were set to 
default values. The aim of the approach is to identify pos-
sible joinpoints, where a significant change in the trend oc-
curs. The method identifies joinpoints based on regression 
models with 0-5 joinpoints. The final model selected was 
the most parsimonious of these, with the estimated annu-
al percent change (EAPC) based on the trend within each 
segment (12). To quantify the trend over the whole period, 
the average annual percent change (AAPC) was calculated. 
The AAPC is computed as a geometric weighted average 
of the EAPC trend analysis, with the weights equal to the 
lengths of each segment during the prespecified fixed in-
terval. If an AAPC lies entirely within a single joinpoint seg-
ment, the AAPC is equal to the EAPC for that segment. In 
these cases, we chose to report the EAPC (29). In describ-
ing trends, the terms “significant increase” or “significant 
decrease” signify that the slope of the trend was statistically 
significant (P < 0.05). For non-statistically significant trends 
(P > 0.05), we used the terms “stable” (for EAPC between 
-0.5% and 0.5%), “non-statistically significant increase” (for 
EAPC>0.5%), and “non-statistically significant decrease” (for 
EAPC<-0.5%). All statistical tests were two sided.
reSulTS
Between 1988 and 2009, there were 785 cases of ALL in 
men and 612 in women, 1881 cases of CLL in men and 
1494 in women, 1084 cases of AML in men and 1057 in 
women, 612 cases of CML in men and 510 in women, with 
a total of 8035 cases, 4362 male and 3673 female. The 
most common leukemia type was CLL, comprising 42% 
of leukemias, followed by AML with 27%, ALL with 17%, 
and CML with 14%.CANCER EPIDEMIOLOGY  118 Croat Med J. 2012;53:115-23
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The  age-standardized  incidence  rates  for  all  subtypes 
were higher in men than in women, more pronounced 
for chronic leukemias (Table 1). Incidence rates increased 
with age, and majority of newly diagnosed cases in the pe-
riod 2005-2009 were in the 65+ age group, except for ALL, 
which presented a bimodal pattern with 51% cases aged 
0-19 and 21% cases in the 65+ age group. For CLL, 75% pa-
tients were older than 65 years (data not shown).
ALL  incidence  showed  a  slight  non-significant  increase, 
while  CLL incidence showed decreases in both sexes (Ta-
ble 2, Figure 1). Between the first and the last observed 
five-year period, AML incidence rate increased by 63% in 
men and 54% in women (Table 1). While the female AML 
incidence was steadily increasing, with EAPC of 2.6% (95% 
confidence interval [CI], 1.0 to 4.3), in men three different 
trend segments were observed, with a significant increase 
of 3.2% (95% CI, 0.3 to 6.2) annually observed since 1998. 
CML incidence in women decreased by 52% between the 
first and the last five-year period, with a continuous signifi-
cant decrease of 3.7% (95% CI, -5.9 to -1.4) annually, while 
it remained stable in men (Table 2, Figure 1).
A total of 5691 deaths were identified, 2759 from lymphoid 
leukemias (1524 men and 1235 women) and 2932 from my-
eloid leukemias (1507 men and 1425 women). No significant 
changes of mortality trends for either lymphatic or myeloid 
leukemias were observed in either sex (Table 2, Figure 2).
NHL was the most common hematopoietic malignancy 
analyzed,  with  3791  diagnosed  men  and  3746  women. 
For both NHL and HL, ASRs were higher for men. NHL in-
cidence increased with age, while HL showed a bimodal 
pattern, with the first peak in the age group 20-29 years, 
and the second peak in the age group 60-69 years (data 
not shown). Between the first and the last five-year peri-
od, the overall increase in NHL incidence was 26% in men 
and 24% in women (Table 1). For men, three different trend 
segments were identified, with AAPC of 1% (95% CI, -3 to 
5.1), while in women the incidence increased significantly 
by 3.2% (95% CI, 1.7 to 4.7) without sharp changes of trend. 
For HL in both sexes, a non-significant increase in the inci-
dence with three different trends was also observed. While 
NHL mortality steadily increased in both sexes, with EAPC 
TABle 1. Average annual numbers of new cases and age-standardized rates (ASr) per 100 000 of leukemia and lymphoma in Croatia, 
1988-1992 and 2005-2009 (using world standard population)
Men Women
1988-1992 2005-2009 1988-1992 2005-2009
N ASr N ASr change (%) N ASr N ASr change (%)
ALL 37 1.99 36 2.25 13 26 1.37 28 1.64 20
CLL 78 2.75 98 2.59 -6 64 1.50 72 1.20 -20
AML 34 1.41 75 2.30 63 36 1.06 64 1.63 54
CML 23 0.85 25 0.74 -13 27 0.77 17 0.37 -52
HL 43 1.77 57 2.32 31 36 1.45 64 2.56 77
NHL 132 5.11 215 6.96 36 120 3.53 234 5.57 58
*Abbreviations: All – acute lymphoblastic leukemia; Cll – chronic lymphocytic leukemia; AMl – acute myeloid leukemia; CMl – chronic myeloid 
leukemia; hl – hodgkin lymphoma; Nhl – non-hodgkin lymphoma.
TABle 2. Average annual percentage changes (AAPC) of 
incidence and mortality of leukemia and lymphoma in Croatia 
with 95% confidence intervals (CI), 1988-2009
Incidence Mortality
AAPC 95% CI AAPC 95% CI
All: All+Cll:
male 1.1 -0.7 to 3.0 -0.3 -1.4 to 0.8
female 1.3 -0.6 to 3.1 0.1 -1.0 to 1.2
Cll:
male -0.4 -1.5 to 0.8
female -0.7 -1.7 to 0.4
AMl: AMl+CMl:
male 1.8 -6.1 to 10.3 0.2 -0.8 to 1.2
female 2.6† 1.0 to 4.3 0.3 -0.8 to 1.3
CMl:
male - 0.5 -2.6 to 1.6
female - 3.7† - 5.9 to -1.4
hl: hl:
male 0.0 -7.2 to 7.8 -5.6† -7.3 to -3.9
female 1.5 -9.9 to 14.4 -3.7† -6.3 to -1.0
Nhl: Nhl:
male 1.0 -3.0 to 5.1 1.6† 0.8 to 2.4
female 3.2† 1.7 to 4.7 1.8† 0.8 to 2.9
*Abbreviations: All – acute lymphoblastic leukemia; Cll – chronic 
lymphocytic leukemia; AMl – acute myeloid leukemia; CMl – chronic 
myeloid leukemia; hl – hodgkin lymphoma; Nhl – non-hodgkin 
lymphoma.
†Significant result.119 Novak et al: Trends of leukemia and lymphoma in Croatia
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of 1.6% (95% CI, 0.8 to 2.4) in men and 1.8% (95% CI, 0.8 
to 2.9) in women, HL mortality markedly decreased, with 
EAPC of -5.6% (95% CI, -7.3 to -3.9) in men and -3.7% (95% 
CI, -6.3 to -1.0) in women (Table 2, Figure 1). The overall de-
creases in HL mortality between the first and the last five-
year periods were more than 50% in both sexes (Table 3).
dISCuSSION
According  to  GLOBOCAN  estimates  for  the  year  2008, 
age-standardized incidence rate of leukemia in Croatia is 
8.6/100 000 in men and 5.3/100 000 in women, which 
is slightly higher than the European average for men 
TABle 3. Average annual numbers of deaths and age-standardized rates (ASr) per 100 000 of leukemia and lymphoma in Croatia, 
1988-1992 and 2005-2009 (using world standard population)
Men Women
1988-1992 2005-2009 1988-1992 2005-2009
N ASr N ASr change (%) N ASr N ASr change (%)
Lymphoid leukemia 59 2.31 80 2.21 -4 49 1.26   68 1.27 1
Myeloid leukemia 52 1.98 76 2.13 8 57 1.59   76 1.68 6
HL 25 0.94 13 0.38 -60 20 0.58   10 0.29 -50
NHL 76 2.86 128 3.59 26 70 1.85 121 2.31 25
*Abbreviations: hl – hodgkin lymphoma, Nhl – non-hodgkin lymphoma.
FIgure 2. Mortality trends of hematopoietic malignancies in Croatia, 1988-2009, rhombs – male; triangles – female; ASr  (W)– age-standardized rate per 
100 000 (using world standard population).CANCER EPIDEMIOLOGY  120 Croat Med J. 2012;53:115-23
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(8.3/100 000)  and  lower  than  the  European  average  for 
women (5.6/100 000). The lowest incidence rate in Europe 
in both sexes is found in Central and Eastern Europe. Age-
standardized mortality rate in Croatian men is 5.3/100 000, 
compared to the European average of 4.9/100 000, while 
the rate in women of 3.0/100 000 equals the European 
average. The lowest rates in both sexes are observed in 
Northern Europe (30). HAEMACARE project group, using 
five large categories of myeloid and five categories of lym-
phoid malignancies in the period 2000-2002 observed the 
lowest leukemia rates in Eastern Europe, which they as-
sumed to be caused by underreporting (31).
We found higher age-standardized incidence and mortal-
ity rates in men than in women. The age and sex distribu-
tion patterns of leukemia in Croatia correspond to those 
observed in other countries (32,33).
Incidence trends of leukemia types vary across countries. 
The stable ALL incidence in Croatia corresponds to trends 
reported in other countries, like the US, UK, and the Neth-
erlands (32,34,35). Increasing CLL incidence rates were re-
ported in Denmark (33) and in Dutch women (35). The 
latter  has  been  attributed  to  increased  surveillance  in 
the scope of the mammography screening program (35). 
AML incidence in Croatia increased in both sexes, which 
is consistent with a Danish study covering the period 
from 1943 to 2003 (33). It was also increasing in the US 
(36) from the mid-1980s to the early 2000. However, in 
the UK it was declining for from 1984 to 1993 (34), while 
in French Department Cote d´Or it showed a relatively 
stable incidence from 1980 to 2004 (37). CML incidence 
trends show lower variation between countries, ie, sever-
al studies showed continued declines, similar to our find-
ings (32-34).
Given the variety of risk factors implicated in the etiol-
ogy of leukemias and lymphomas, it is hard to hypothe-
size possible reasons for the observed incidence trends. 
In addition to true changes of incidence, they might be 
caused by changes of diagnostic procedures or increased 
surveillance due to screening programs, as well as changes 
of classification or reassignment of one diagnostic entity 
to the other (31,35,38). Based on the results from 13 Eu-
ropean countries, the marked increase in NHL incidence 
trends could be partly explained by reassignment of HL 
as NHL and consequent decreases in HL trends (38). The 
increase in NHL incidence in Croatia was not as promi-
nent as reported in other countries; however, while the 
incidence has leveled off in the US and most of the 
European countries, in Croatia it still continues (36,38). HL 
incidence trends vary across countries, and are usually less 
stable due to smaller number of cases (38). Three different 
trend segments observed in male NHL and HL incidence in 
both sexes in Croatia probably represent a consequence of 
registration, rather than changes in background incidence 
rates. Underreporting of lymphomas was evident during 
the war in Croatia (1991-1995), while the peak of incidence 
in 1999 can be attributed to the introduction of a new data 
source (1), and possible registration of some prevalent cas-
es. We cannot assess the extent of possible reassignment 
of HL to NHL diagnosis; however, the divergent NHL and 
HL mortality trends observed in Croatia would support this 
hypothesis.
Mortality trends, in addition to changes in incidence or 
classification of disease, reflect improvements of treatment 
and survival. Decreasing leukemia mortality trends were 
reported  in Western  countries  between  late  1960s  and 
late 1990s (39,40). In the same period, in Eastern European 
countries, the decline was limited to younger age-groups 
(15-44 years), while the age-standardized rates did not sig-
nificantly change. When we analyzed age-specific mortal-
ity trends of our study population, no significant decreases 
were observed even in the youngest age-group (15-44) for 
either sex or leukemia type.
Decreases in mortality are preceded by improvements of 
survival. The recent increasing trends of leukemia survival 
in the US and Europe have been attributed to improve-
ments in care, more specific diagnosis and treatment, as 
well as improved supportive care (41-43). Even though 
the improvements of leukemia survival are more promi-
nent in younger patients, in the study of recent survival 
trends in younger patients in Croatia, no improvements 
have been observed in the period between 2000 and 
2006 (44).
While the decreasing mortality trends for HL have been re-
ported throughout Europe (45), the declines in NHL mor-
tality in the European Union have started only from the 
mid-1990s. In Eastern European countries, as well as in Cro-
atia, increasing mortality trends are still observed (46).
The  last  decades  have  witnessed  several  major  break-
throughs in the treatment of leukemias and lymphomas, 
such as introduction of allogenic hematopoietic stem cell 
transplantation (usually restricted to patients younger than 
65 years), and more recent introduction of tyrosine-kinase 
inhibitor imatinib in the treatment of CML in 2001 (47), and 121 Novak et al: Trends of leukemia and lymphoma in Croatia
www.cmj.hr
monoclonal antibodies (rituximab) in the treatment of NHL 
in 1997 (48). After the launch in the US, these treatments 
were introduced to Europe (49). In Croatia, imatinib was 
introduced in the first line of treatment only in 2003, and 
rituximab in 2006. Also the bone marrow transplantation 
rates in Croatia were very low. In 2003, the hematopoietic 
allogenic stem cell transplant rate in Croatia was 56 per 10 
million, which is about two- to 3-fold lower than in West-
ern European countries (50). The transplantation rates in-
creased only after the “I want life!” campaign was started in 
2006, during which the number of voluntary bone marrow 
donors in Croatia increased from 150 to 20 000 (51), and 
with an increased number of centers for stem cell trans-
plantation (52). However, these recent improvements have 
not reflected on our data.
The limitation of our study was the inability to distinguish 
between the mortality of acute and chronic leukemias, and 
detect possible improvements in a specific leukemia type, 
such as in the SEER9 database, where divergent trends of 
mortality from myeloid leukemias are observed (increas-
ing AML mortality and markedly decreasing CML mortal-
ity) (36).
In spite of the long tradition and high expertise of Croa-
tian hematology (53), the delayed introduction of optimal 
treatment modalities resulted in less favorable mortality 
trends than in Western European countries. As currently 
the most up-to date diagnostics and best tailored treat-
ments are available and covered by health insurance, we 
hope that, in addition to already declining HL mortality 
trend, improvements of leukemia and NHL survival and 
subsequent declines of mortality will follow.
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